Navigation Links
Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative Stress
Date:1/6/2014

GREENWOOD VILLAGE, Colo., Jan. 6, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center (Nahariya, Israel) and the University of Thessaly (Larissa, Greece). These two leading oxidative stress research groups will utilize Luoxis' proprietary RedoxSYS oxidation-reduction potential (ORP) diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

(Logo: http://photos.prnewswire.com/prnh/20130718/MM49747LOGO)

Western Galilee Medical Center, based in Nahariya, Israel, is a leading institution in the study of oxidative stress. Dr. Shifra Sela and Dr. Batya Kristal will serve as the principle investigators studying oxidation-reduction potential in hypertension and hemodialysis.  Both researchers have studied oxidative stress for over 20 years, and their work has been extensively published.

The University of Thessaly, comprising faculties of Medicine, Biochemistry and Biotechnology in Larissa, Greece, is an established institution supported by University Hospital of Larissa and focused on patient care and research, including the study of oxidative stress in critical conditions.  Dr. Maria Karapetsa, Dr. Epaminondas Zakynthinos, Dr. Dimitrios Kouretas, and Dr. Dimitrios Stagos will serve as the principle investigators studying oxidation-reduction potential in sepsis and physical exertion. All researchers have multiple publications to their credit.

"We are pleased to be partnering with Western Galilee Medical Center and the University of Thessaly on these important research projects," said Josh Disbrow, Chief Executive Officer of Luoxis. "Luoxis and these prominent research teams share a strong interest in advancing the study of oxidative stress, and we believe incorporating oxidation-reduction potential measurements into current diagnostic practice will significantly advance assessment of human oxidative stress in prevalent and challenging patient populations."

Both research centers, in collaboration with Dr. David Bar-Or, Ampio and Luoxis Chief Scientific Officer, expect to publish the results of their research in peer-reviewed publications following completion of the studies. 

About the RedoxSYS Diagnostic System
The RedoxSYS diagnostic system is a patented diagnostic device with accompanying disposable sensors that rapidly measures and reports unique oxidative stress parameters by analyzing a single drop of a biologic specimen. Prior to the development of the RedoxSYS diagnostic system, oxidative stress measurement was incomplete, time consuming and impractical in a clinical setting. The RedoxSYS diagnostic system enables robust and rapid assessment of oxidative stress via measurement of oxidation-reduction potential (ORP) in the clinical setting.  ORP is a homeostatic parameter capturing the balance of oxidants and reductants in a biologic system, a complete measure of oxidative stress.  Multiple clinical trials have been completed using the RedoxSYS diagnostic system and have demonstrated the predictive value of ORP across numerous conditions.

About Luoxis
Luoxis is a biotechnology company focused on the development and global commercialization of the RedoxSYS diagnostic system.  The RedoxSYS diagnostic system is comprised of a portable analyzer and disposable sensors that rapidly measure the level of oxidative stress and antioxidant reserves in biologic specimens via assessment of oxidation-reduction potential (ORP). ORP has been shown to be an important measure in both critical and chronic illnesses and is a novel marker of patient morbidity across a wide range of conditions. There are numerous clinical indications for this homeostatic parameter for which there is no currently available test. Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
2. Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
3. Quantum Materials Establishes Milestone as First Company to Deliver Tetrapod Quantum Dot Samples to LCD Display Manufacturer
4. Texas Childrens Hospital establishes the Jeffrey Modell Diagnostic & Research Center with a donation from the Jeffrey Modell Foundation
5. PA Governor Corbett: Americure Rx Establishes Operations in Lehigh Valley; Creates 51 Jobs
6. Winterhawk Consulting Establishes Partnership with Onapsis Inc to expand their SAP security offerings using Onapsis X1.
7. ICV Partners Establishes Dialysis Treatment Platform With Acquisition Of Atlantis Healthcare Group Puerto Rico, Inc.
8. Life Technologies Establishes International Influenza Network
9. H. D. Smith Establishes Specialty Solutions Organization And Realigns Senior Leadership To Support Growing Geographic Reach, Diversified Businesses
10. PQ Bypass Graduates from the Fogarty Institute for Innovation, Establishes Independent Operations
11. HYCOR Establishes Center Of Operations In Kassel, Germany To Provide Dedicated Support To European Distributors And Customers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology:
(Date:7/21/2017)... CA (PRWEB) , ... July 21, 2017 , ... West ... “Tu” Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West ... 27 years of experience in dermatology, skin cancer , and more. She graduated ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of transitions ... timeline. This effect isolates horizontal and vertical lines of pixels and sorts their pixels ... or flipping animation and can be changed using a drop-down menu. Create amazing and ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... firm headquartered in Houston, is pleased to announce their expansion to the Midwest ... housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John Peck ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network of medical ... , directed by Dr. Russell Horine, DC to their exclusive list of medical professionals. ... Russell Horine serving as the clinic director and his son Dr. Lee Horine and ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced ... Dunbar received his BS in Biology from LSU, graduating summa cum laude. He attended ... President. After his residency in St. Louis, Dr. Dunbar moved to New York to ...
Breaking Medicine News(10 mins):